WHO Praise Oxford University for COVID-19 Vaccine Trials

W1siziisijiwmjavmdcvmjevmtavntkvmzmvnze1l0dsb2jhbe5ld3mymcaomskgkdeplnbuzyjdlfsiccisinrodw1iiiwiodawedy1mfx1mdazyyjdxq

Sarah Peddie

The World Health Organisation praises Oxford University as it leads the way in finding a vaccine for Covid-19 and brands it as ‘good news’. 

Speaking at a press conference in Geneva on Monday (20 July) executive director of the WHO emergencies programme Dr Mike Ryan applauded the data published by the university along with AstraZeneca on a potential vaccine. The data was published in The Lancet.

However, the organisation highlighted that it is still too early and they need more evidence of its effectiveness. 

More than 1,000 participants between the ages of 18-55 were involved in the first phase of the trial. Researchers at Oxford said that the vaccine produced antibodies and killer T-cells to fight off the infection and this apparently lasts for two months.

At the conference, Dr Ryan stated: “In generating T-cell responses and generating neutralising antibodies, this is a positive result. But again, there is a long way to go. 

“We now need to move into larger-scale real-world trials.”

The findings from the trial have also shown that the vaccine was well-tolerated. The most common side effects from taking the vaccine was fatigue and headaches. Other side effects included pain at the injection site, aching muscles, chills and a fever. 

Public health officials have stated that people all around the world cannot go back to “normal” life until there is a vaccine.

If you are looking for a new job in the medical sector then register with Odyssey Recruitment today and we could help you find the perfect job.